Article Text

Download PDFPDF
  1. Maria Stavrou1,
  2. Deborah Smith1,
  3. Pauline Shaw2,
  4. Dominika Raciborska1,
  5. Eli Silber2,
  6. Peter Brex2,
  7. Gavin Giovannoni1,
  8. Klaus Schmierer1,
  9. Benjamin Turner1
  1. 1 Barts Health NHS Trust
  2. 2 King's College


Background Fingolimod is a licensed and NICE-approved disease modifying therapy (DMT) for people with relapsing multiple sclerosis (pwRMS).

Objective To analyse the ‘real world’ experience of Fingolimod in two MS centres (Barts Health and King's College).

Methods Patients were identified through electronic medical records (March 2013–December 2015). Demographics, MS history and follow-up data were analysed.

Results 215 pwRMS were prescribed Fingolimod as second-line DMT in 77.6% (n=167) and first-line in 21% (n=45). 71.6% switched from Interferon-beta or Glatiramer acetate. Thirteen JCV positive pwRMS switched from Natalizumab to Fingolimod, due to risk of PML. Fingolimod was discontinued in 15% (n=32) due to adverse effects (most frequently headache, in one case infection), pregnancy and ongoing disease activity (n=10). The absolute lymphocyte count was <0.2 in 7 cases. 16.3% (n=35) had at least one relapse during the observation period, 46% of which had ongoing MRI activity.

Conclusions Our experience of Fingolimod as a treatment for pwRMS closely resembles the data from the original phase III clinical trials and supports the short-term safety and efficacy of Fingolimod in clinical practice. This collaboration between MS centres provides useful insights into the ‘real world’ experience of benefits and risks of DMTs for pwRMS.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.